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A B S T R A C T
Background
Hereditary haemochromatosis is a genetic disorder related to proteins involved in iron transport, resulting in iron load and deposition of
iron in various tissues of the body. This iron overload leads to complications including liver cirrhosis (and related complications such as
liver failure and hepatocellular carcinoma), cardiac failure, cardiac arrhythmias, impotence, diabetes, arthritis, and skin pigmentation.
Phlebotomy (venesection or ’blood letting’) is the currently recommended treatment for hereditary haemochromatosis. The optimal
treatment of hereditary haemochromatosis remains controversial.
Objectives
To assess the comparative benefits and harms of different interventions in the treatment of hereditary haemochromatosis through a
network meta-analysis and to generate rankings of the available treatments according to their safety and efficacy. However, we found
only one comparison. Therefore, we did not perform the network meta-analysis and we assessed the comparative benefits and harms
of different interventions using standard Cochrane methodology.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, Science Citation Index Expanded,
World Health Organization International Clinical Trials Registry Platform, and randomised clinical trials registers to March 2016 to
identify randomised clinical trials on treatments for hereditary haemochromatosis.
Selection criteria
We included only randomised clinical trials (irrespective of language, blinding, or publication status) in participants with hereditary
haemochromatosis. We excluded trials which included participants who had previously undergone liver transplantation. We considered
any of the various interventions compared with each other or with inactive treatment.
Data collection and analysis
We used standard methodological procedures expected by Cochrane. We calculated the odds ratio (OR) and rate ratio with 95%
confidence intervals (CI) using both fixed-effect and random-effects models with RevMan 5 based on available-participant analysis.
We assessed risk of bias according to Cochrane, controlled risk of random errors with Trial Sequential Analysis, and assessed the quality
of the evidence using GRADE.
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Main results
Three trials with 146 participants met the inclusion criteria of this review. Two parallel group trials with 100 participants provided
information on one or more outcomes. The remaining trial was a cross-over trial, with no usable data for analysis. All the trials were
at high risk of bias. Overall, all the evidence was of very low quality. All three trials compared erythrocytapheresis (removal of red cells
only, instead of whole blood) versus phlebotomy. Two of the trials shared the same first author. The mean or median age in the three
trials ranged from 42 to 55 years. None of the trials reported whether the included participants were symptomatic or asymptomatic
or a mixture of both. Two trials were conducted in people who were haemochromatosis treatment-naive. The trial that provided most
data for this review excluded people with malignancy, heart failure, and serious cardiac arrhythmias. We found no trials assessing iron-
chelating agents.
Only one of the trials with 38 participants reported no short-term mortality and no serious adverse events at the end of the short-term
follow-up (eight months). Two trials reported the proportion of people with adverse events: 10/49 (20.4%) in the erythrocytapheresis
group versus 11/51 (21.6%) in the phlebotomy group. One of these two trials provided data on adverse event rates (42.1 events
per 100 participants with erythrocytapheresis versus 52.6 events per 100 participants with phlebotomy). There was no evidence of
differences in the proportion of people with adverse events and the number of adverse events (serious and non-serious) between the
groups (proportion of people with adverse events: OR 0.93, 95% CI 0.36 to 2.43; participants = 100; trials = 2; number of adverse
events: rate ratio 0.80, 95% CI 0.32 to 2.03; participants = 38; trial = 1). There was no difference between the groups regarding short-
term health-related quality of life (mean difference (MD) 1.00, 95% CI -10.80 to 12.80; participants = 38; trials = 1). This outcome
was measured using EQ-VAS (range: 0 to 100 where a higher score indicates better health-related quality of life). None of the trials
reported mortality beyond one year, health-related quality of life beyond one year, liver transplantation, decompensated liver disease,
cirrhosis, hepatocellular carcinoma, diabetes, or cardiovascular complications during the long-term follow-up.
The two trials that provided data for this review were funded by parties with no vested interest in the results; the source of funding of
the third trial was not reported.
Authors’ conclusions
There is currently insufficient evidence to determine whether erythrocytapheresis is beneficial or harmful compared with phlebotomy.
Phlebotomy has less equipment requirements and remains the treatment of choice in people with hereditary haemochromatosis who
require blood letting in some form. However, it should be noted that there is no evidence from randomised clinical trials that blood
letting in any form is beneficial in people with hereditary haemochromatosis. Having said this, a trial including no treatment is unlikely
to be conducted. Future trials should compare different frequencies of phlebotomy and erythrocytapheresis versus phlebotomy with
and without different iron-chelating agents compared with each other, and with placebo. Such trials should include long-term follow-
up of participants (e.g. using national record linkage databases) to determine whether treatments are beneficial or harmful in terms of
clinical outcomes such as deaths, health-related quality of life, liver damage and its consequences, heart damage and its consequences,
and other outcomes that are of importance to people with hereditary haemochromatosis.
P L A I N L A N G U A G E S U M M A R Y
Treatments for hereditary haemochromatosis
Background
Hereditary haemochromatosis is an inherited genetic disorder (derived from one’s parents) resulting in excessive iron accumulation
in the body. Some people develop liver damage leading to liver failure, heart damage leading to heart failure, impotence (inability
for a man to have an erection or orgasm), diabetes, arthritis (joint pain and swelling), and skin pigmentation (colouring) because of
excessive iron accumulation. Several treatments are used to treat hereditary haemochromatosis but the best way is not clear.We searched
for randomised clinical trials (well-design clinical studies where people are randomly put into one of two or more treatment groups)
reported to March 2016. We included trials in which participants had not had a liver transplant. Apart from using standard Cochrane
methods which allow comparison of only two treatments at a time (direct comparison), we planned to use an advanced method which
allows comparison of the many different treatments which are individually compared in the trials (network meta-analysis). However,
because there was only one comparison, we used standard Cochrane methodology.
Study characteristics
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We identified three trials. Two trials with 100 participants provided information on one or more outcomes (measures of how well
the treatments worked). The trials compared phlebotomy (removal of blood or ’blood letting’) versus erythrocytapheresis (removal
of blood, separation of red cells (which carry oxygen in the blood), and return of the remaining parts of the blood). Two trials were
conducted in people who had not undergone previous treatment for haemochromatosis. The trial that provided most data for this
review excluded people with cancer, heart failure, and serious irregular heartbeats.
Source of funding: the two trials that provided data for this review were funded by parties with no vested interest in the results; the
source of funding of the third trial was not reported.
Key results
There were no deaths or serious complications in the short term in either group in the only trial that reported this information. There
was no evidence of any difference in the percentage of people with any complications, the number of complications per person, and
short-term health-related quality of life (a measure of a person’s satisfaction with their life and health) between the treatments. None
of the trials reported deaths beyond one year, health-related quality of life beyond one year, liver transplantation, severe liver damage,
liver failure, liver cancer, diabetes, heart failure, or stroke during the long term. There is currently insufficient evidence to determine
whether erythrocytapheresis is beneficial or harmful compared with phlebotomy. Erythrocytapheresis requires special equipment, while
phlebotomy does not. So, phlebotomy remains the treatment of choice in people with hereditary haemochromatosis even though there
is no evidence from randomised clinical trials that blood letting is beneficial. Having said this, a randomised clinical trial including no
treatment is unlikely to be conducted.
Quality of evidence
The overall quality of evidence was very low as the trials were at high risk of bias, which means that there is possibility of making wrong
conclusions overestimating benefits or underestimating harms of treatments because of the way that the studies were conducted. Further
high-quality randomised clinical trials to identify how often blood letting should be performed and those comparing erythrocytapheresis
versus blood letting are required. Such trials should include long-term monitoring of participants (perhaps by linking health records in
some countries).
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Erythrocytapheresis versus phlebotomy for hereditary haemochromatosis
Patient or population: people with hereditary haemochromatosis
Settings: secondary or tert iary
Intervention: erythrocytapheresis
Comparison: phlebotomy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Phlebotomy Therapeutic erythrocyta-
pheresis
Long- term mortality None of the included trials reported mortality beyond 1 year
M ortality
Follow-up period: 8 months
There was no mortality in either group in the short-term in the 1 trial that reported
this information
38
(1 study)
⊕©©©
Very low1,2
Serious adverse events
Follow-up period: 8 months
There were no serious adverse events in either group in the 1 trial that reported this
information
38
(1 study)
⊕©©©
Very low1,2
Health- related quality of
life
EQ-VAS. Scale f rom: 0 to
100.
Follow-up period: 8 months
The mean health-related
quality of lif e in the control
groups was
68
The mean health-related
quality of lif e in the inter-
vent ion groups was
1 higher
(10.8 lower to 12.8 higher)
- 38
(1 study)
⊕©©©
Very low1,2
Health- related quality of
life beyond one year
None of the included trials reported health-related quality of lif e beyond one year
* The basis for the assumed risk is the mean control group proport ion or control event rate. The corresponding risk (and its 95% conf idence interval) is based on the assumed
risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval.
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GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1 Downgraded one level for risk of bias.
2 Downgraded two levels for imprecision (one level for small sample size and one level for wide conf idence intervals).
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Hereditary haemochromatosis is a genetic disorder related to pro-
teins involved in iron transport, resulting in iron load and depo-
sition of iron in various tissues of the body (Adams 2007). The
most common mutation causing hereditary haemochromatosis is
substitution of cysteine with tyrosine at position 282 (C282Y)
of the HFE gene (Feder 1996; Pietrangelo 2004; Adams 2007;
Bardou-Jacquet 2014). This is an autosomal-recessive genetic dis-
order (i.e. it can manifest itself only when both alleles (copies of
the gene in both chromosomes) carry the mutation) (Feder 1996;
Pietrangelo 2004; Adams 2007; Bardou-Jacquet 2014). However,
compound heterozygosity with another allele H63D (substitu-
tion of histamine with aspartic acid at position 63) (i.e. one copy
of the C282Y mutated human haemochromatosis protein (HFE)
gene and one copy of the H63D mutated HFE gene) can also
result in manifestation of haemochromatosis (Feder 1996; van
Bokhoven 2011). Several other mutations related to the HFE pro-
tein and other proteins involved in iron transport, namely ferro-
portin, hepcidin, transferrin receptor-2, haemojuvelin, and ceru-
loplasmin, can lead to hereditary haemochromatosis (Pietrangelo
2004; Adams 2007; van Bokhoven 2011). Carriers of the auto-
somal-recessive mutated HFE gene (either the C282Y or H63D
allele in one of the chromosomes) varies globally and depends on
ethnic origin. In the US, the prevalence of the carrier state is about
5.4% for C282Y and 13.5% for H63D alleles (Steinberg 2001).
Approximately 0.3% of the general population in the US are ho-
mozygous for C282Y, 1.9% are homozygous for H63D, and 2%
have C282Y/H63D compound heterozygosity (Steinberg 2001).
The frequencies of C282Y and H63D alleles are more common
in non-Hispanic white people compared to non-Hispanic black
people and Mexican-American people (Steinberg 2001). In Eu-
rope, there is significant variation in different countries with the
frequency of C282Y more common in countries such as Ireland
and the UK (Lucotte 2003). Overall, 0% to 28% of people carry
at least one C282Y allele in different countries in Europe (Mercier
1998; Cassanelli 2001; Lucotte 2003; Ropero 2006; Voicu 2009);
and 23% to 30% carry at least one H63D allele (Cassanelli 2001;
Ropero 2006; Voicu 2009). However, on average, only 0.3% of
people are homozygous for the C282Y allele. In Australia, screen-
ing of people of Northern Europe ancestry revealed that 0.7% of
people were homozygous for the C282Y mutation and an addi-
tional 2.4% had C282Y/H63D compound heterozygosity (Allen
2008).
Diagnosis of hereditary haemochromatosis is suspected by abnor-
mal serum iron studies such as serum ferritin and transferrin sat-
uration, and established by the presence of C282Y homozygous
gene products and the presence of other known rarer mutations
(van Bokhoven 2011). Liver iron stores measured by magnetic res-
onance imaging or liver biopsy may be helpful in identifying ele-
vated iron stores in the liver (Bacon 2011; van Bokhoven 2011).
The proportion of people with haemochromatosis-predisposing
mutations who develop clinical symptoms of iron overload is very
controversial. Asymptomatic elevation of serum ferritin and trans-
ferrin saturation (i.e. screen-detected hereditary haemochromato-
sis) is a common mode of clinical presentation (Bardou-Jacquet
2014). In symptomatic people, common symptoms related to
hereditary haemochromatosis at the time of diagnosis are poor gen-
eral health, fatigue, malaise, diabetes, and arthralgia (Pietrangelo
2004; Allen 2008; van Bokhoven 2011). Complications related to
hereditary haemochromatosis include liver cirrhosis (and related
complications such as liver failure and hepatocellular carcinoma),
cardiac failure, cardiac arrhythmias, impotence, diabetes, arthri-
tis, and skin pigmentation (Pietrangelo 2004; Schmitt 2005; van
Bokhoven 2011; Bardou-Jacquet 2014). While some researchers
state that 28% to 50% of men and 1.4% to 44% of women
homozygous for haemochromatosis-predisposing mutations de-
velop symptoms (Bradley 1996; Allen 2008), other researchers
point out that the frequency of symptoms commonly attributed
to haemochromatosis such as poor general health, fatigue, malaise,
diabetes, and arthralgia were similar between people homozy-
gous for haemochromatosis-predisposing mutations and the gen-
eral population (Beutler 2002). Therefore, it is not clear whether
these symptoms are related to haemochromatosis at all. However,
it should be pointed out that people homozygous for haemochro-
matosis-predisposing mutations had more frequent liver disorders
compared to the general population (Beutler 2002). Overall, the
odds of developing hepatocellular carcinoma and porphyria cu-
tanea tarda (skin blisters in areas of the body exposed to sun-
light) were higher in C282Y homozygotes and C282Y/H63D
compound heterozygotes compared to people in control groups
(Ellervik 2007). Approximately one-third of symptomatic people
with C282Y homozygosity and a mean age of 50 years referred
to a tertiary care centre die over 20 years (Wojcik 2002; Schmitt
2005). Although the symptoms related to hereditary haemochro-
matosis are thought to be due to iron overload and some studies
have indicated a relationship between symptoms and a serum fer-
ritin level of 1000 µg/L (Allen 2008), there is currently no firm
evidence for a relationship between symptoms and the degree of
iron overload (Beutler 2002; van Bokhoven 2011). While screen-
ing of family members and the general population have been ad-
vocated by some researchers (Pietrangelo 2004; Bacon 2011; de
Graaff 2015), other researchers found no evidence of any tangi-
ble benefit of screening based on systematic reviews of clinical
effectiveness (Schmitt 2005; Whitlock 2006). However, asymp-
tomatic elevation of serum ferritin and transferrin saturation (i.e.
screen-detected hereditary haemochromatosis) is a commonmode
of clinical presentation (Bardou-Jacquet 2014).
Description of the intervention
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The main treatments for hereditary haemochromatosis include
phlebotomy (venesection or blood letting), erythrocytapheresis
(removal of red cells only instead of removal of whole blood), and
administration of iron-chelating agents such as desferrioxamine
(van Bokhoven 2011). Removal of 500 mL of blood per week
guided by serum transferrin levels and haemoglobin levels is rec-
ommended (van Bokhoven 2011). The major problems with reg-
ular phlebotomy are venous access and the requirement to visit
a healthcare facility for treatment (van Bokhoven 2011). While
there are no absolute contraindications for phlebotomy, the rel-
ative contraindications include severe heart disease and anaemia
(Assi 2014), and possibly hypoproteinaemia.
Erythrocytapheresis involves removal of red cells only instead
of whole blood and requires specialist equipment. However, the
number of treatments can be reduced compared to regular phle-
botomy as more iron can be removed per session (van Bokhoven
2011; Rombout-Sestrienkova 2012). Desferrioxamine is usually
administered subcutaneously, intramuscularly, or intravenously
(Martindale 2011). A starting dose of 500 mg is recommended
and the drug may be administered three to seven times a week
(Martindale 2011). Adverse reactions of desferrioxamine include
severe allergy, arthralgia, pain at injection site, gastrointestinal
symptoms, tachycardia, and thrombocytopenia (Martindale 2011;
van Bokhoven 2011). Newer iron-chelating agents such as de-
ferasirox have also been used for the treatment of primary hered-
itary haemochromatosis (Cancado 2015). Deferasirox is an oral
chelating agent and appears to have equivalent efficacy and safety
profiles as desferrioxamine (Vichinsky 2007; Pennell 2014). This
review will not cover lifestyle modifications such as reduced alco-
hol consumption and dietary changes.
How the intervention might work
Since red blood cells contain iron as a component of haemoglo-
bin, their removal (by erythrocytapheresis or phlebotomy) reduces
body iron content, which could potentially diminish iron deposi-
tion in tissues and the subsequent complications. Desferrioxam-
ine is an iron-chelating agent that might work by removing iron
deposition from the tissues (Martindale 2011).
Why it is important to do this review
The optimal treatment of hereditary haemochromatosis is not
known. Currently, both the European Association for the Study of
the Liver (EASL) and American Association for the Study of Liver
Diseases (AASLD) recommend phlebotomy as the treatment of
choice (EASL 2010; Bacon 2011). One randomised clinical trial
reported that erythrocytapheresis required fewer sessions than ve-
nesection todecrease ironoverload (Rombout-Sestrienkova 2012).
It is also not clear whether any of these measures decrease the de-
velopment of complications. So, there is clearly discordance be-
tween the evidence and recommendations. Networkmeta-analysis
allows combination of the direct evidence and indirect evidence,
and allows ranking of different treatments in terms of the different
outcomes (Salanti 2011; Salanti 2012). There has beennonetwork
meta-analysis on the comparative effectiveness of different inter-
ventions in the treatment of hereditary haemochromatosis. This
systematic review and attempted network meta-analysis provides
evidence from randomised clinical trials on the role of different
medical interventions in the treatment of people with hereditary
haemochromatosis.
O B J E C T I V E S
To assess the comparative benefits and harms of different interven-
tions in the treatment of hereditary haemochromatosis through
meta-analysis and to generate rankings of the available treatments
according to their safety and efficacy. However, we found only one
comparison. When more trials become available, we will attempt
to conduct network meta-analysis in order to generate rankings
of the available treatments according to their safety and efficacy.
This is why we retain the planned methodology for network meta-
analysis in our Appendix 1. Once data appear allowing for the
conduct of network meta-analysis, this Appendix 1 will be moved
back into the Methods section.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered only randomised clinical trials for this network
meta-analysis irrespective of language, publication status, or date
of publication. We excluded studies of other design because of the
risk of bias in such studies. We are all aware that such exclusions
make us focus muchmore on potential benefits and not fully assess
the risks of serious adverse events as well as risks of adverse events.
Types of participants
We included participants with hereditary haemochromatosis irre-
spective of the method of diagnosis of the disease or the presence
of symptoms. We exclude randomised clinical trials in which par-
ticipants had undergone liver transplantation previously.
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Types of interventions
Weplanned to include the following interventions that are possible
treatments for hereditary haemochromatosis and can be compared
with each other or with no active treatment.
The interventions that we considered were:
• phlebotomy;
• desferrioxamine;
• erythrocytapheresis.
The above list was not exhaustive. If we identified any other in-
terventions that we were not aware of, we planned to consider
them as eligible and include them in the review if they were used
primarily for the treatment of hereditary haemochromatosis. We
excluded trials that did not include at least two or more of the
included interventions.
Types of outcome measures
We planned to assess the comparative benefits and harms of avail-
able pharmacological interventions aimed at treating people with
hereditary haemochromatosis for the following outcomes.
Primary outcomes
• Long-term mortality (time to death; maximal follow-up).
• Mortality:
◦ short-term mortality (up to one year);
◦ medium-term mortality (one to five years).
• Adverse events (within three months after cessation of
treatment). Depending on the availability of data, we attempted
to classify adverse effects as serious or non-serious. We defined a
non-serious adverse event as any untoward medical occurrence
not necessarily having a causal relationship with the treatment
but resulting in a dose reduction or discontinuation of treatment
(any time after commencement of treatment) (ICH-GCP 1997).
We defined a serious adverse event as any event that would
increase mortality; was life threatening; required hospitalisation;
resulted in persistent or significant disability; was a congenital
anomaly/birth defect; or any important medical event that might
have jeopardised the person or required intervention to prevent
it. We used the definition used by trial authors for non-serious
and serious adverse events:
◦ proportion of participants with serious adverse events;
◦ number of serious adverse events;
◦ proportion of participants with any type of adverse
event;
◦ number of any type of adverse event.
• Health-related quality of life as defined in the included
trials using a validated scale such as EQ-5D or 36-item Short
Form (SF-36) (EuroQol 2014; Ware 2014):
◦ short-term (up to one year);
◦ medium-term (one to five years);
◦ long-term (beyond five years).
We planned to consider long-term health-related quality of life
more important than short-term or medium-term health-related
quality of life, although short-term and medium-term health-re-
lated quality of life are also important primary outcomes.
Secondary outcomes
• Liver transplantation (maximal follow-up):
◦ proportion of participants with liver transplantation;
◦ time to liver transplantation.
• Decompensated liver disease (maximal follow-up):
◦ proportion of participants with decompensated liver
disease;
◦ time to liver decompensation.
• Cirrhosis (any cirrhosis with or without clinical symptoms
and with or without decompensation) (maximal follow-up):
◦ proportion of participants with cirrhosis;
◦ time to cirrhosis.
• Hepatocellular carcinoma (maximal follow-up).
• Diabetes (maximal follow-up).
• Cardiovascular complications such as cardiac failure,
myocardial infarction, and stroke (maximal follow-up).
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Tri-
als (CENTRAL; 2016, Issue 3), MEDLINE (OvidSP), Embase
(OvidSP), and Science Citation Index Expanded (Web of Knowl-
edge) (Royle 2003) from inception to 29 March 2016 for ran-
domised clinical trials comparing two or more of the above in-
terventions. We searched for all possible comparisons formed
by the interventions of interest. To identify further ongoing or
completed trials, we also searched the World Health Organiza-
tion International Clinical Trials Registry Platform search por-
tal (www.who.int/ictrp/en), which searches various trial registers,
including ISRCTN and ClinicalTrials.gov on 29 March 2016.
Appendix 2 shows the search strategies used.
Searching other resources
We searched the references of the identified trials and the existing
Cochrane Reviews on hereditary haemochromatosis to identify
additional trials for inclusion.
Data collection and analysis
Selection of studies
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Two review authors (EB and MK) independently identified the
trials for inclusion by screening the titles and abstracts. We sought
full-text articles for any references that at least one of the review
authors identified for potential inclusion. We selected the trials
for inclusion based on the full-text articles. We planned to list the
excluded full-text references with reasons for their exclusion in the
’Characteristics of excluded studies’ table. We listed any ongoing
trials identified primarily through the search of the clinical trial
registers for further follow-up. We resolved discrepancies through
discussion and by arbitration with KG, DT, and ET.
Data extraction and management
Two review authors (EB and MK) independently extracted the
following data.
• Outcome data (for each outcome and for each treatment
arm whenever applicable):
◦ number of participants randomised;
◦ number of participants included for the analysis;
◦ number of participants with events for binary
outcomes, mean and standard deviation for continuous
outcomes, number of events for count outcomes, and the
number of participants with events and the mean follow-up
period for time-to-event outcomes;
◦ definition of outcomes or scale used if appropriate.
• Data on potential effect modifiers:
◦ participant characteristics such as age, sex,
comorbidities, proportion of symptomatic participants, method
of diagnosis, proportion of people with C282Y homozygosity,
previous use of treatments;
◦ details of the intervention and control (including dose
(in the case of desferrioxamine) or target reduction (in the case of
phlebotomy and erythrocytapheresis, frequency, and duration);
◦ details of any cointerventions;
◦ risk of bias (assessment of risk of bias in included
studies).
• Other data:
◦ year and language of publication;
◦ country in which the participants were recruited;
◦ year(s) in which the trial was conducted;
◦ inclusion and exclusion criteria;
◦ follow-up time points of the outcome.
If available, we planned to obtain the data separately for symp-
tomatic participants and asymptomatic participants from the re-
port.We attempted to contact trial authors when there was unclear
or missing information, or when there was doubt whether trials
shared the same participants, completely or partially (by identi-
fying common authors and centres), or if we needed clarification
whether the trial report was duplicated. We resolved any differ-
ences in opinion through discussion.
Assessment of risk of bias in included studies
We followed the guidance given in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011) and in the
Cochrane Hepato-Biliary Module (Gluud 2015) to assess the risk
of bias in included studies. Specifically, we assessed the risk of bias
in included trials for the following domains (Schulz 1995; Moher
1998; Kjaergard 2001; Wood 2008; Savovi 2012a; Savovi
2012b; Lundh 2017).
Allocation sequence generation
• Low risk of bias: the study authors performed sequence
generation using computer random number generation or a
random number table. Drawing lots, tossing a coin, shuffling
cards, and throwing dice were adequate if an independent person
not otherwise involved in the study performed them.
• Unclear risk of bias: the study authors did not specify the
method of sequence generation.
• High risk of bias: the sequence generation method was not
random. We planned to only include such studies for assessment
of harms.
Allocation concealment
• Low risk of bias: the participant allocations could not have
been foreseen in advance of, or during, enrolment. A central and
independent randomisation unit controlled allocation. The
investigators were unaware of the allocation sequence (e.g. if the
allocation sequence was hidden in sequentially numbered,
opaque, and sealed envelopes).
• Unclear risk of bias: the study authors did not describe the
method used to conceal the allocation so the intervention
allocations may have been foreseen before, or during, enrolment.
• High risk of bias: it is likely that the investigators who
assigned the participants knew the allocation sequence. We
planned to only include such studies for assessment of harms.
Blinding of participants and personnel
• Low risk of bias: any of the following: no blinding or
incomplete blinding, but the review authors judged that the
outcome was not likely to be influenced by lack of blinding; or
blinding of participants and key study personnel ensured, and it
was unlikely that the blinding could have been broken.
• Unclear risk of bias: any of the following: insufficient
information to permit judgement of ’low risk’ or ’high risk’; or
the trial did not address this outcome.
• High risk of bias: any of the following: no blinding or
incomplete blinding, and the outcome was likely to be
influenced by lack of blinding; or blinding of key study
participants and personnel attempted, but likely that the
blinding could have been broken, and the outcome was likely to
be influenced by lack of blinding.
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Blinded outcome assessment
• Low risk of bias: any of the following: no blinding of
outcome assessment, but the review authors judged that the
outcome measurement was not likely to be influenced by lack of
blinding; or blinding of outcome assessment ensured, and
unlikely that the blinding could have been broken.
• Unclear risk of bias: any of the following: insufficient
information to permit judgement of ’low risk’ or ’high risk’; or
the trial did not address this outcome.
• High risk of bias: any of the following: no blinding of
outcome assessment, and the outcome measurement was likely
to be influenced by lack of blinding; or blinding of outcome
assessment, but likely that the blinding could have been broken,
and the outcome measurement was likely to be influenced by
lack of blinding.
Incomplete outcome data
• Low risk of bias: missing data were unlikely to make
treatment effects depart from plausible values. The study used
sufficient methods, such as multiple imputation, to handle
missing data.
• Unclear risk of bias: there was insufficient information to
assess whether missing data in combination with the method
used to handle missing data were likely to induce bias on the
results.
• High risk of bias: the results were likely to be biased due to
missing data.
Selective outcome reporting
• Low risk of bias: the trial reported the following predefined
outcomes: mortality, decompensated liver disease, requirement
for transplantation, and treatment-related adverse events. If the
original trial protocol was available, the outcomes should have
been those called for in that protocol. If the trial protocol was
obtained from a trial registry (e.g. www.clinicaltrials.gov), the
outcomes sought should have been those enumerated in the
original protocol if the trial protocol was registered before or at
the time that the trial was begun. If the trial protocol was
registered after the trial was begun, those outcomes were not
considered to be reliable.
• Unclear risk of bias: not all predefined, or clinically relevant
and reasonably expected, outcomes were reported fully, or it was
unclear whether data on these outcomes were recorded or not.
• High risk of bias: one or more predefined or clinically
relevant and reasonably expected outcomes were not reported,
despite the fact that data on these outcomes should have been
available and even recorded.
For-profit bias
• Low risk of bias: the trial appeared to be free of industry
sponsorship or other type of for-profit support that could
manipulate the trial design, conductance, or results of the trial.
• Uncertain risk of bias: the trial may or may not have been
free of for-profit bias as no information on clinical trial support
or sponsorship was provided.
• High risk of bias: the trial was sponsored by industry or
received other type of for-profit support.
Other bias
• Low risk of bias: the trial appeared to be free of other
components (e.g. inappropriate control or dose or
administration of control, baseline differences, early stopping)
that could put it at risk of bias.
• Uncertain risk of bias: the trial may or may not have been
free of other components that could put it at risk of bias.
• High risk of bias: there were other factors in the trial that
could put it at risk of bias (e.g. inappropriate control or dose or
administration of control, baseline differences, early stopping).
We considered a trial at low risk of bias if we assessed the trial as
at low risk of bias across all domains. We considered a trial at low
risk of bias for an outcome if we assessed the trial as at low risk of
bias across all study level domains. Otherwise, we considered the
trials at uncertain risk of bias or at high risk of bias regarding one
or more domains as at high risk of bias.
Measures of treatment effect
For dichotomous variables (e.g. short-term and medium-term
mortality or liver transplantation, proportion of participants with
adverse events, decompensated liver disease, cirrhosis, hepatocel-
lular carcinoma, or diabetes), we calculated the odds ratio (OR)
with 95% confidence intervals (CI). For continuous variables (e.g.
quality of life reported on the same scale), we calculated the mean
difference (MD) with 95% CI. We planned to use standardised
mean differences with 95% CI for quality of life if included trials
used different scales. For count outcomes (e.g. number of adverse
events), we calculated the rate ratio with 95% CI. For time-to-
event data (e.g. long-termmortality or requirement for liver trans-
plantation, time to liver decompensation, and time to cirrhosis),
we planned to use the hazard ratio with 95% CIs. We also cal-
culated Trial Sequential Analysis-adjusted CI to control random
errors (Thorlund 2011).
Unit of analysis issues
The unit of analysis was the person with hereditary haemochro-
matosis according to the intervention group to which they were
randomly assigned.
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Cluster randomised clinical trials
We found no cluster randomised clinical trials. If we found them,
we planned to include them provided that the effect estimate ad-
justed for cluster correlation was available.
Cross-over randomised clinical trials
We found one cross-over randomised clinical trial. We planned
to only include the outcomes after the period of first treatment
since hereditary haemochromatosis is a chronic disease and the
treatments could potentially have a residual effect. However, the
cross-over trial did not report any outcomes prior to the cross-
over.
Trials with multiple treatment groups
We collected data for all trial treatment groups that met the inclu-
sion criteria.
Dealing with missing data
We performed an intention-to-treat analysis whenever possible
(Newell 1992). Otherwise, we planned to use the data that were
available to us (e.g. a trial might have reported only per-protocol
analysis results). As such ’per-protocol’ analyses may be biased,
we planned to conduct best-worst case scenario analyses (good
outcome in intervention group and bad outcome in control group)
andworst-best case scenario analyses (bad outcome in intervention
group and good outcome in control group) as sensitivity analyses
whenever possible but did not perform this because there were no
post-randomisation dropouts in either trial that provided data.
For continuous outcomes, we planned to impute the standard de-
viation from P values according to guidance given in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011). If
the data were likely to be normally distributed, we planned to use
the median for meta-analysis when the mean was not available. If
it was not possible to calculate the standard deviation from the P
value or the CIs, we planned to impute the standard deviation us-
ing the largest standard deviation in other trials for that outcome.
This form of imputation may decrease the weight of the study for
calculation of MDs and may bias the effect estimate to no effect
for calculation of standardised mean differences (Higgins 2011).
Assessment of heterogeneity
We assessed clinical andmethodological heterogeneity by carefully
examining the characteristics and design of included trials. We
planned to assess the presence of clinical heterogeneity by com-
paring effect estimates in the presence or absence of symptoms,
different targets of iron reduction, and different doses of desfer-
rioxamine or different methods of erythrocytapheresis or phle-
botomy, and the doses of the pharmacological treatments. Dif-
ferent study designs and risk of bias may contribute to method-
ological heterogeneity. If we identified substantial heterogeneity,
clinical, methodological, or statistical, we explored and address
heterogeneity in a subgroup analysis (see Subgroup analysis and
investigation of heterogeneity). We used the I2 test and Chi2 test
for heterogeneity, and overlapping of CIs to assess heterogeneity.
Assessment of reporting biases
We planned to use visual asymmetry on a funnel plot to explore
reporting bias in the presence of at least 10 trials that could be
included for a direct comparison (Egger 1997;Macaskill 2001). In
the presence of heterogeneity that could be explained by subgroup
analysis, we planned to produce a funnel plot for each subgroup
in the presence of the adequate number of trials. We planned to
use the linear regression approach described by Egger 1997 to
determine funnel plot asymmetry.
We also considered selective reporting and non-reporting of trials
(identified from searching the trial registers) as evidence of report-
ing bias.
Data synthesis
We performed the meta-analyses according to the recommenda-
tions of The Cochrane Collaboration (Higgins 2011), using the
software package Review Manager 5 (RevMan 2014). We used
a random-effects model (DerSimonian 1986) and a fixed-effect
model (Demets 1987). In the case of a discrepancy between the
two models, we have reported both results; otherwise, we have
reported only the results from the fixed-effect model.
Calculation of required information size and Trial Sequential
Analysis
For calculation of the required information size, see Appendix
3. We performed Trial Sequential Analysis to control the risks
of random errors (Wetterslev 2008; Thorlund 2011; TSA 2011)
when there were at least two trials included in the meta-analysis.
We used an alpha error of 2.5% (Jakobsen 2014), power of 90%
(beta error of 10%), a relative risk reduction of 20%, a control
group proportion observed in the trials, and the diversity observed
in the meta-analysis.
Subgroup analysis and investigation of heterogeneity
Weplanned to assess the differences in the effect estimates between
the following subgroups.
• Trials with low risk of bias compared to trials with high risk
of bias.
• Participants with symptomatic compared to participants
with asymptomatic hereditary haemochromatosis.
• Different targets of iron reduction.
• Different doses of desferrioxamine or different methods of
erythrocytapheresis or phlebotomy.
We planned to use the chi2 test for subgroup differences to identify
subgroup differences.
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Sensitivity analysis
If a trial reported only per-protocol analysis results, we planned to
re-analyse the results using the best-worst case scenario and worst-
best case scenario analyses as sensitivity analyseswhenever possible.
However, we did not perform this because both trials that provided
data for this review had no post-randomisation dropouts.
Presentation of results and GRADE assessments
We reported mortality, serious adverse events, and health-related
quality of life in a ’Summary of findings’ table format, downgrad-
ing the quality of evidence for risk of bias, inconsistency, indirect-
ness, imprecision, and publication bias using GRADE (Guyatt
2011).
R E S U L T S
Description of studies
Results of the search
We identified 3852 references through electronic searches ofCEN-
TRAL (N = 312), MEDLINE (N = 2245), Embase (N = 489),
Science Citation Index Expanded (N = 690), World Health Orga-
nization International Clinical Trials Registry Platform (N = 30),
and randomised controlled trials registers (N = 86). After the re-
moval of 814 duplicates, we obtained 3038 references. We then
excluded 3033 clearly irrelevant references through screening ti-
tles and reading abstracts. We retrieved five references for further
assessment. No references were identified through scanning ref-
erence lists of the identified randomised trials. Four of the ref-
erences were reports of three trials which fulfilled the inclusion
criteria of our review (Rombout-Sestrienkova 2012; Sundic 2014;
Rombout-Sestrienkova 2016; Characteristics of included studies
table). One reference is an ongoing trial without any interim data,
comparing erythrocytapheresis versus plasmapheresis (Ong 2015;
Characteristics of ongoing studies table). The reference flow is
summarised in the study flow diagram (Figure 1).
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Figure 1. Study flow diagram.
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Included studies
Three trials included 146 participants (Rombout-Sestrienkova
2012; Sundic 2014; Rombout-Sestrienkova 2016). All the three
trials were two-armed and compared erythrocytapheresis versus
phlebotomy. Two trials were simple parallel randomised clinical
trials (Rombout-Sestrienkova 2012; Sundic 2014). The remain-
ing trial was a cross-over randomised clinical trial in which partic-
ipants were randomised to receive therapeutic erythrocytapheresis
or phlebotomy (Rombout-Sestrienkova 2016). After one year, the
participants were crossed-over to receive the opposite treatment
(Rombout-Sestrienkova 2016). Two trials with 100 participants
provided data for analyses (Rombout-Sestrienkova 2012; Sundic
2014).
None of the trials reported whether they included symptomatic
or asymptomatic participants, or a mixture of both. Two trials
which provided data for this review were conducted in people
who had not undergone previous treatment for haemochromatosis
(Rombout-Sestrienkova 2012; Sundic 2014). The trial which did
not provide data for this review included only people on main-
tenance therapy for haemochromatosis (Rombout-Sestrienkova
2016). The trial that provided most data for this review excluded
people with malignancy, heart failure, and serious cardiac arrhyth-
mias (Rombout-Sestrienkova 2012).
One trial carried out erythrocytapheresis bi-weekly (not clear
whether the authors meant this to be once every two weeks or
twice weekly) (Sundic 2014), one trial once every two weeks
(Rombout-Sestrienkova 2012), and on trial variably depending
upon serum ferritin level (Rombout-Sestrienkova 2016). Two tri-
als carried out phlebotomy once a week (Rombout-Sestrienkova
2012; Sundic 2014), and one trial variably depending upon
serum ferritin level (Rombout-Sestrienkova 2016). The amount
of red blood cells withdrawn during each treatment of erythro-
cytapheresis was 350 mL to 800 mL (Rombout-Sestrienkova
2012; Sundic 2014; Rombout-Sestrienkova 2016). The amount
of blood withdrawn during each treatment of phlebotomy was
450 mL to 500 mL (Rombout-Sestrienkova 2012; Sundic 2014;
Rombout-Sestrienkova 2016). The treatment duration in one trial
was 12 weeks (Sundic 2014), was one year (after which the people
crossed-over) in one trial (Rombout-Sestrienkova 2016), and was
variable depending upon the amount of iron to be removed in
one trial (Rombout-Sestrienkova 2012). All the trials used serum
ferritin level of 50 µg/L or less as the target for treatment.
The mean or median age in the trials ranged from 42 to 55 years.
The proportion of females was 9.7% in Sundic 2014 and 26.3%
in Rombout-Sestrienkova 2012. Rombout-Sestrienkova 2016 did
not report this information.
Two trials that provided data for this review were funded by parties
with no vested interest in the results (Rombout-Sestrienkova 2012;
Sundic 2014); the other trial did not report the source of funding
(Rombout-Sestrienkova 2016).
Excluded studies
We excluded no studies that we sought full text for.
Risk of bias in included studies
The risk of bias is summarised in Figure 2 and Figure 3. As shown
in Figure 3, all the trials were at overall high risk of bias.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
One trial was at low risk of selection bias due to random sequence
generation (Sundic 2014). The remaining trials were at unclear
risk of random sequence generation (Rombout-Sestrienkova 2012;
Rombout-Sestrienkova 2016).One trial was at low risk of selection
bias due to allocation concealment (Rombout-Sestrienkova 2012).
The remaining trials were at unclear risk of allocation concealment
(Sundic 2014; Rombout-Sestrienkova 2016).
Blinding
None of the trials were at low risk of performance or detection bias
due to blinding of participants, personnel, and outcome assessors.
All the trials were at high risk of performance bias (Rombout-
Sestrienkova 2012; Sundic 2014; Rombout-Sestrienkova 2016).
One trial was at high risk of detection bias (Rombout-Sestrienkova
2016); the remaining two trials were at unclear risk of detection
bias (Rombout-Sestrienkova 2012; Sundic 2014).
Incomplete outcome data
Two trials were at low risk of attrition bias due to incomplete
outcome data (Rombout-Sestrienkova 2012; Sundic 2014). The
remaining trial was at high risk of attrition bias due to incomplete
outcome data (Rombout-Sestrienkova 2016).
Selective reporting
One trial was at low risk of reporting bias due to selective outcome
reporting (Rombout-Sestrienkova 2012). The remaining two tri-
als were at high risk of reporting bias due to selective outcome
reporting (Sundic 2014; Rombout-Sestrienkova 2016).
Other potential sources of bias
Two trials were at low risk of for-profit bias (Rombout-
Sestrienkova 2012; Sundic 2014). One trial was at unclear risk
of for-profit bias since the source of funding was not reported
(Rombout-Sestrienkova 2016). All the trials were at low risk of
’other’ bias.
Effects of interventions
See: Summary
of findings for the main comparison Erythrocytapheresis versus
phlebotomy for hereditary haemochromatosis
Long-term mortality
None of the trials reported long-term mortality.
Mortality
One trial (38 participants) reported short-term mortality at eight
months (Rombout-Sestrienkova 2012). There was no mortality
in either group. None of the trials reported mortality beyond one
year.
Serious adverse events
One trial (38 participants) reported serious adverse events (
Rombout-Sestrienkova 2012). There were no serious adverse
events in either group.
All adverse events
Two trials with 100 participants reported proportion of par-
ticipants with any adverse events (Rombout-Sestrienkova 2012;
Sundic 2014). The proportion of people with any adverse events
in the erythrocytapheresis group was 10/49 (20.4%) versus 11/
51 (21.6%) in the phlebotomy group. There was no evidence of
difference in all adverse events between the groups (OR 0.93, 95%
CI 0.36 to 2.43; participants = 100; trials = 2; I2 = 0%). There was
no alteration in the results by using the random-effects model.
One of these two trials with 38 participants also reported the num-
ber of adverse events (Rombout-Sestrienkova 2012). The adverse
event rate was 42.1 events per 100 participants in the erythrocy-
tapheresis group and 52.6 events per 100 participants in the phle-
botomy groups. There was no evidence of difference in all adverse
events between the groups (rate ratio 0.80, 95% CI 0.32 to 2.03;
participants = 38; trials = 1).
Health-related quality of life
One trial with 38 participants reported short-term health-related
quality of life (up to one year) (Rombout-Sestrienkova 2012) us-
ing EQ-VAS (EuroQol 2014) on a scale of 0 to 100 with higher
numbers indicating better health-related quality of life. There was
no significant difference in health-related quality of life between
the groups (MD 1.00, 95% CI -10.80 to 12.80; participants = 38;
trials = 1). None of the trials reported health-related quality of life
beyond one year.
Liver transplantation
None of the trials reported liver transplantation.
Decompensated liver disease
None of the trials reported decompensated liver disease.
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Cirrhosis
None of the trials reported cirrhosis.
Hepatocellular carcinoma
None of the trials reported hepatocellular carcinoma.
Diabetes
None of the trials reported diabetes.
Cardiovascular complications
None of the trials reported cardiovascular complications such as
cardiac failure, myocardial infarction, and stroke at maximal fol-
low-up.
Subgroup analysis
We did not perform any of the subgroup analyses because none of
the trials were at low risk of bias, the trials did not report whether
the participants were symptomatic or asymptomatic, all the trials
used serum ferritin level of 50 µg/L or less as the target, and the
trials used similarmethods of erythrocytapheresis andphlebotomy.
Trial Sequential Analysis
Only one comparison had more than one trial and was eligible for
Trial Sequential Analysis. As shown in Figure 4, the accrued sample
size was only a small fraction of the diversity-adjusted required
information size (DARIS); therefore, the boundaries could not be
drawn. There was a high risk of random errors. The TSA-adjusted
CI could not be calculated as there was too little information to
be used.
Figure 4. Trial Sequential Analysis of adverse events (proportion) performed using an alpha error of 2.5%,
power of 90% (beta error of 10%), relative risk reduction of 20%, control group proportion (Pc) observed in
trials (21.6% for proportion of people with adverse events), and observed diversity (0%) shows that the accrued
sample size was only a small fraction of the diversity-adjusted required information size (DARIS) that the
boundaries could not be drawn. The Z-curve (blue line) does not cross the conventional boundaries (dotted
green line). There was a high risk of random errors.
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Reporting bias
We did not explore reporting bias using a funnel plot because of
few trials included in the review.
Quality of evidence
All the evidence available was downgraded to very low quality of
evidence because of the risk of bias in the trials (downgraded one
level for risk of bias) and imprecision (downgraded one level for
small sample size and one more level for wide CIs). There was no
evidence of indirectness, heterogeneity, or publication bias. So, we
did not downgrade for these domains (Summary of findings for
the main comparison).
D I S C U S S I O N
Summary of main results
In this review, we included three trials (146 partici-
pants) (Rombout-Sestrienkova 2012; Sundic 2014; Rombout-
Sestrienkova 2016). However, one of these trials provide no infor-
mation for this review (Rombout-Sestrienkova 2016). Only one
trial was included inmost of the outcomes (Rombout-Sestrienkova
2012). The only outcome of interest for this review and reported in
more than one trial was proportion of people with adverse events
(Rombout-Sestrienkova 2012; Sundic 2014). There was no short-
term mortality or serious adverse events in either group in the one
trial that reported these outcomes (Rombout-Sestrienkova 2012).
There were no statistically significant differences between erythro-
cytapheresis and phlebotomy in the proportion of people with
adverse events, number of adverse events, and short-term health-
related quality of life. None of the trials reported mortality be-
yond one year, health-related quality of life beyond one year, liver
transplantation, decompensated liver disease, cirrhosis, hepatocel-
lular carcinoma, diabetes, or cardiovascular complications in the
long-term. In summary, there was no evidence of a difference be-
tween erythrocytapheresis and phlebotomy in people with hered-
itary haemochromatosis.
Overall completeness and applicability of
evidence
We planned to include all treatments used for hereditary
haemochromatosis but found that the only comparison reported
was erythrocytapheresis versus phlebotomy. The current rec-
ommended treatment for hereditary haemochromatosis is phle-
botomy and the trials were conducted relatively recently. There-
fore, the findings of this review are applicable in the current clin-
ical setting. The trials did not report whether the participants
were symptomatic or asymptomatic. They probably included par-
ticipants who required blood letting of some form regardless of
symptoms based on the ferritin and transferrin levels. Therefore,
the findings of the review are likely to be applicable in symp-
tomatic and asymptomatic people. Both the trials that contributed
data for this review included only treatment-naive people, that is,
people who had not received previous treatments for hereditary
haemochromatosis. Therefore, the findings of the review are appli-
cable only in people with hereditary haemochromatosis who had
not received treatment previously. Finally, the trial that provided
most of the information for this review excluded people with ma-
lignancy, serious cardiac arrhythmias, heart failure, and epilepsy.
Therefore, the findings of this review are not applicable in such
people.
Phlebotomy requires minimal equipment while erythrocytaphere-
sis requires special equipment to perform the procedure. Since
there is no evidence to suggest that erythrocytapheresis is benefi-
cial versus phlebotomy, there is no need for hospitals to buy special
equipment, based on currently available evidence.
Quality of the evidence
The overall quality of evidence was very low for all the outcomes.
All the trials were at high risk of bias, mainly because blinding of
participants and healthcare providers was not performed in any of
the trials. The sample size was small for all the comparisons. The
only outcome in which Trial Sequential Analysis was attempted
showed that the sample size was less than 5% of the required
information size to identify a relative risk reduction of 20%. There
were also wide CIs for all the comparisons.
Potential biases in the review process
We followed the guidance of theCochrane Handbook for Systematic
Reviews of Interventions with two review authors independently
selecting studies and extracting data. We performed a thorough
search of literature. However, the search period included the pre-
mandatory trial registration era and it is possible that we missed
some trials on treatments that were not effective or were harmful
or were not reported at all.
We only included randomised clinical trials which are known to
focus mostly on benefits and do not collect and report harms in a
detailed manner. According to our choice of studies (i.e. only ran-
domised clinical trials), we might have missed a large number of
studies that address reporting of harms. Accordingly, this review is
biased towards benefits ignoring harms. We did not search for in-
terventions and trials registered at regulatory authorities (e.g., FDA
(US Food and Drug Administration); EMA (EuropeanMedicines
Agency), etc). This may have overlooked trials and as such trials
usually are unpublished, the lack of inclusion of such trials may
make our comparisons look more advantageous than they really
are.
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Agreements and disagreements with other
studies or reviews
There have been no previous systematic reviews on this topic.
The authors of the trial that provided most information for
this review concluded that erythrocytapheresis is a highly effec-
tive treatment to reduce iron overload, and that from a soci-
etal perspective, it might potentially also be a cost-saving therapy
(Rombout-Sestrienkova 2012). Our findings show that it is too
early to know whether erythrocytapheresis is beneficial or harmful
compared with phlebotomy. While we did not collect the cost in-
formation for this review, we noted that the costs of purchasing the
equipment and maintenance of the equipment was not included
in the cost calculations. This is likely to alter the conclusions about
the difference between treatment costs. It is also not clear whether
blinding of participants was performed. Lack of blinding of partic-
ipants to treatment may cause biased estimate of the costs related
to productivity loss. Therefore, the existing evidence did not allow
us to support the trial authors’ conclusions.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is currently insufficient evidence to determine whether
erythrocytapheresis is beneficial or harmful compared with
phlebotomy. Phlebotomy has less equipment requirements and
remains the treatment of choice in people with hereditary
haemochromatosis who require blood letting in some form. How-
ever, it should be noted that there is no evidence from randomised
clinical trials that blood letting in any form is beneficial in peo-
ple with hereditary haemochromatosis. Having said this, a trial
including no treatment is unlikely to be conducted in future.
Implications for research
Future trials should compare different frequencies of phlebotomy
and erythrocytapheresis versus phlebotomy with or without iron-
chelating agents compared with each other and with placebo. Such
trials should include long-term follow-up of participants (e.g. us-
ing national record linkage databases) to determine whether treat-
ments are beneficial or harmful in terms of clinical outcomes such
as deaths, health-related quality of life, liver damage and its conse-
quences, heart damage and its consequences, and other outcomes
that are of importance to people with hereditary haemochromato-
sis. The trials should be designed using guidance from SPIRIT
statement (Standard Protocol Items: Recommendations for Inter-
ventional Trials; Chan 2013) and reported according to theCON-
SORT statement (Schulz 2010).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Rombout-Sestrienkova 2012
Methods Randomised clinical trial.
Participants Country: Netherlands.
Number randomised: 38.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 38.
Mean age: 52 years.
Number of women: 10 (26.3%).
Symptomatic: not stated.
Asymptomatic: not stated.
Mean follow-up period: 8 months.
Target used for iron reduction: serum ferritin ≤ 50 µg/L.
Inclusion criteria:
• Homozygosis for C282Y.
• Participants treatment naive.
• Aged 18 to 80 years.
• Weight ≥ 50 kg.
• Transferrin saturation > 50%.
• Serum ferritin > 450 mg/L.
• Haemoglobin concentration ≥ 7.5 mmol/L (120 g/L) in women and ≥ 8.0
mmol/L (128 g/L) in men.
Exclusion criteria:
• Malignancy.
• Serious cardiac arrhythmias.
• Heart failure.
• Epilepsy.
Interventions Participants were randomly assigned to 2 groups.
Group 1: therapeutic erythrocytapheresis (n = 19).
Further details: 350 mL to 800 mL of red blood cells once every 2 weeks
Group 2: phlebotomy (n = 19).
Further details: 500 mL of whole blood once weekly.
Treatment duration: variable depending upon the iron to be removed
Outcomes Mortality, adverse events, and health-related quality of life
Notes We attempted to contact the corresponding author to obtain additional information on
risk of bias and outcomes in June 2015. We did not receive any reply
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Rombout-Sestrienkova 2012 (Continued)
Random sequence generation (selection
bias)
Unclear risk Quote: “patients were randomly assigned in a 1:1 ratio by an
independent person working as quality assurance manager”
Allocation concealment (selection bias) Low risk Quote: “patients were randomly assigned in a 1:1 ratio by an
independent person working as quality assurance manager”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “single-blind”.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “single-blind”.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no post-randomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias Low risk Quote: “This work was performed with the support of the
Sanquin Blood Bank grants 03-006”
Other bias Low risk Comment: no other risk of bias.
Rombout-Sestrienkova 2016
Methods Randomised clinical trial.
Participants Country: Netherlands.
Number randomised: 53.
Post-randomisation dropouts: 7 (13.2%).
Revised sample size: 46.
Mean age: 55 years.
Number of women: not stated.
Symptomatic: not stated.
Asymptomatic: not stated.
Mean follow-up period: 1 year (after this there was cross-over)
Target used for iron reduction: serum ferritin ≤ 50 µg/L.
Inclusion criteria:
• Homozygous for C282Y mutation.
• Aged ≥ 18 years.
• Weight ≥ 50 kg.
• Currently treated in hospital setting with maintenance phlebotomy therapy for ≥
6 months.
• Signed informed consent.
• Willingness to fill out additional questionnaires at 3 points in time.
Exclusion criteria:
• Excessive overweight (body mass index > 35 kg/m2).
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Rombout-Sestrienkova 2016 (Continued)
• Chelating therapy.
• Forced dietary regimen.
• Pregnancy.
• Malignancy.
Interventions Participants were randomly assigned to 2 groups.
Group 1: therapeutic erythrocytapheresis (n = 20).
Further details: 350 mL to 800 mL red blood cells; variable frequency depending on
serum ferritin level
Group 2: phlebotomy (n = 26).
Further details: 500 mL per single treatment; variable frequency depending on serum
ferritin level
Treatment duration: 1 year.
Outcomes None of our outcomes of interest were reported at the end of the first treatment
Notes Reasons for post-randomisation dropouts: not stated clearly.
We attempted to contact the corresponding author in June 2015 to obtain additional
information on risk of bias and outcomes. We did not receive any reply
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: probably not blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: probably not blinded.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: important outcomes such asmortality and com-
plications were not reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias.
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Sundic 2014
Methods Randomised clinical trial.
Participants Country: Norway.
Number randomised: 62.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 62.
Mean age: 42 years.
Number of women: 6 (9.7%).
Symptomatic: not stated.
Asymptomatic: not stated.
Mean follow-up period (for all groups): 3 months.
Target used for iron reduction: serum ferritin ≤ 50 µg/L.
Inclusion criteria:
• Aged ≥ 18 years.
• No previous treatment for haemochromatosis.
• Diagnosis of haemochromatosis, defined as: presence of a homozygous genotype
for C282Y or H63D or compound heterozygous genotype for C282Y and H63D and
serum ferritin > 300 ng/mL or a transferrin saturation > 50% OR heterozygous C282Y
genotype and ferritin levels > 500 ng/mL or transferrin saturation > 50%.
Exclusion criteria:
• Atypical haemochromatosis without any documented genetic aberration or
exclusively due to mutations other than C282Y and H63D.
• Bodyweight < 65 kg.
• Initial haemoglobin level < 13.5 g/dL.
Interventions Participants were randomly assigned to 2 groups.
Group 1: therapeutic erythrocytapheresis (n = 30).
Further details: 400 mL per single treatment bi-weekly*.
Group 2: phlebotomy (n = 32).
Further details: 450 mL per single treatment weekly.
Treatment duration: 12 weeks.
Outcomes Adverse events.
Notes We attempted to contact the corresponding author in June 2015 to obtain additional
information on risk of bias and outcomes. We did not receive any reply
* It was unclear whether the authors meant ’bi-weekly’ to be once every two weeks or
twice weekly
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The randomisation procedure was centralised to
one of the participating centres, using a randomly generated
sequence”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
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Sundic 2014 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “different treatment”.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were 6 dropouts/withdrawal but data re-
garding tolerance reported
Selective reporting (reporting bias) High risk Comment: no data about mortality but just tolerability.
For-profit bias Low risk Quote: “Grants fromHelse Vest RHF and Helse Fonna HF
(public hospital trusts)”
Other bias Low risk Comment: no other risk of bias.
Characteristics of ongoing studies [ordered by study ID]
Ong 2015
Trial name or title Mi-iron
Methods Randomised clinical trial
Participants Inclusion criteria:
• Aged 18 to 70 years.
• HFE p.C282Y homozygous.
• Serum ferritin between 300 µg/L and 1000 µg/L.
• Previously or currently raised transferrin saturation.
Exclusion criteria:
• Hereditary haemochromatosis due to other genotypes.
• Venesection in the past 2 years for treatment of hereditary haemochromatosis.
• Other risk factor(s) for liver injury including hepatitis B or C, excess alcohol consumption (> 60 g/day
in men, 40 g/day in women), body mass index ≥ 35 kg/m2.
• Pregnant women.
Interventions Erythrocytapheresis versus plasmapheresis
Outcomes Modified Fatigue Impact Scale
Medical Outcomes Study 36-item short form V.2
Hospital Anxiety and Depression Scale
Arthritis Impact Measurement Scales 2 short form
Starting date June 2012
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Ong 2015 (Continued)
Contact information Martin Delatycki (martin.delatycki@ghsv.org.au)
Notes
HFE = human haemochromatosis protein.
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D A T A A N D A N A L Y S E S
Comparison 1. Therapeutic erythrocytapheresis versus phlebotomy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Adverse events (proportion) 2 100 Odds Ratio (M-H, Fixed, 95% CI) 0.93 [0.36, 2.43]
2 Adverse events (number) 1 Rate Ratio (Fixed, 95% CI) Totals not selected
3 Health-related quality of life
(EQ-VAS)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Therapeutic erythrocytapheresis versus phlebotomy, Outcome 1 Adverse
events (proportion).
Review: Interventions for hereditary haemochromatosis: an attempted network meta-analysis
Comparison: 1 Therapeutic erythrocytapheresis versus phlebotomy
Outcome: 1 Adverse events (proportion)
Study or subgroup
Therapeutic
erythrocyta-
pheresis Phlebotomy Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rombout-Sestrienkova 2012 3/19 5/19 48.6 % 0.53 [ 0.11, 2.60 ]
Sundic 2014 7/30 6/32 51.4 % 1.32 [ 0.39, 4.50 ]
Total (95% CI) 49 51 100.0 % 0.93 [ 0.36, 2.43 ]
Total events: 10 (Therapeutic erythrocytapheresis), 11 (Phlebotomy)
Heterogeneity: Chi2 = 0.80, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours erythrocytapheresis Favours phlebotomy
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Analysis 1.2. Comparison 1 Therapeutic erythrocytapheresis versus phlebotomy, Outcome 2 Adverse
events (number).
Review: Interventions for hereditary haemochromatosis: an attempted network meta-analysis
Comparison: 1 Therapeutic erythrocytapheresis versus phlebotomy
Outcome: 2 Adverse events (number)
Study or subgroup
Therapeutic
erythrocyta-
pheresis Phlebotomy log [Rate Ratio] Rate Ratio Rate Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Rombout-Sestrienkova 2012 19 19 -0.22314 (0.474342) 0.80 [ 0.32, 2.03 ]
0.2 0.5 1 2 5
Favours erythrocytapheresis Favours phlebotomy
Analysis 1.3. Comparison 1 Therapeutic erythrocytapheresis versus phlebotomy, Outcome 3 Health-
related quality of life (EQ-VAS).
Review: Interventions for hereditary haemochromatosis: an attempted network meta-analysis
Comparison: 1 Therapeutic erythrocytapheresis versus phlebotomy
Outcome: 3 Health-related quality of life (EQ-VAS)
Study or subgroup
Therapeutic
erythrocyta-
pheresis Phlebotomy
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Rombout-Sestrienkova 2012 19 69 (20) 19 68 (17) 1.00 [ -10.80, 12.80 ]
-20 -10 0 10 20
Favours phlebotomy Favours erythrocytapheresis
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A P P E N D I C E S
Appendix 1. Methods for network meta-analysis if we find this is possible in the future
Measures of treatment effect
Relative treatment effects
For dichotomous variables (e.g. proportion of participants with serious adverse events or any adverse events), we will calculate the odds
ratio with 95% credible interval (or Bayesian confidence interval) (Severini 1993). For continuous variables (e.g. quality of life reported
on the same scale), we will calculate the mean difference with 95% credible interval. We will use standardised mean difference values
with 95% credible interval for quality of life if included trials use different scales. For count outcomes (e.g. number of adverse events
and serious adverse events), we will calculate the rate ratio with 95% credible interval. For time-to-event data (e.g. mortality at maximal
follow-up), we will calculate hazard ratio with 95% credible interval.
Relative ranking
We will estimate the ranking probabilities for all treatments of being at each possible rank for each intervention. Then, we will obtain
the surface under the cumulative ranking curve (SUCRA) (cumulative probability) and rankogram (Salanti 2011; Chaimani 2013).
Unit of analysis issues
We will collect data for all trial treatment groups that meet the inclusion criteria. The codes for analysis, that we will use, accounts for
the correlation between the effect sizes from trials with more than two groups.
Assessment of heterogeneity
We will assess clinical and methodological heterogeneity by carefully examining the characteristics and design of included trials. We
will assess the presence of clinical heterogeneity by comparing effect estimates under different categories of potential effect modifiers.
Different study designs and risk of bias may contribute to methodological heterogeneity.
We will assess the statistical heterogeneity by comparing the results of the fixed-effect model meta-analysis and the random-effects
model meta-analysis, between-study standard deviation (tau2 and comparing this with values reported in the study of the distribution
of between-study heterogeneity (Turner 2012)), and by calculating I2 (using Stata/SE 14.2). If we identify substantial heterogeneity,
clinical, methodological, or statistical, we will explore and address heterogeneity in a subgroup analysis (see ‘Subgroup analysis and
investigation of heterogeneity for network meta-analysis’ section).
Assessment of transitivity across treatment comparisons
We will evaluate the plausibility of transitivity assumption (the assumption that the participants included in the different studies with
different immunosuppressive regimens can be considered to be a part of a multi-arm randomised clinical trial and could potentially
have been randomised to any of the treatments) (Salanti 2012). In other words, any participant that meets the inclusion criteria is, in
principle, equally likely to be randomised to any of the above eligible interventions. If there is any concern that the clinical safety and
effectiveness are dependent upon the effect modifiers, we will continue to do traditional Cochrane pairwise comparisons and we will
not perform a network meta-analysis on all participant subgroups.
Assessment of reporting biases
For the network meta-analysis, we will judge the reporting bias by the completeness of the search (i.e. searching various databases and
including conference abstracts), as we do not currently find any meaningful order to perform a comparison-adjusted funnel plot as
suggested by Chaimani 2012. However, if we find any meaningful order, for example, the control group used depended upon the year
of conduct of the trial, we will use comparison-adjusted funnel plot as suggested by Chaimani 2012.
Data synthesis
Methods for indirect and mixed comparisons
We will conduct network meta-analyses to compare multiple interventions simultaneously for each of the primary and secondary
outcomes. Network meta-analysis combines direct evidence within trials and indirect evidence across trials (Mills 2012).We will obtain
a network plot to ensure that the trials were connected by treatments using Stata/SE 14.2 (Chaimani 2013). We will exclude any trials
that were not connected to the network. We will conduct a Bayesian network meta-analysis using the Markov chain Monte Carlo
method in OpenBUGS 3.2.3 as per the guidance from the National Institute for Health and Care Excellence (NICE) Decision Support
Unit (DSU) documents (Dias 2014a). We will model the treatment contrast (i.e. log odds ratio for binary outcomes, mean difference
or standardised mean difference for continuous outcomes, log rate ratio for count outcomes, and log hazard ratio for time-to-event
outcomes) for any two interventions (’functional parameters’) as a function of comparisons between each individual intervention and
an arbitrarily selected reference group (’basic parameters’) (Lu 2006) using appropriate likelihood functions and links. We will use
binomial likelihood and logit link for binary outcomes, Poisson likelihood and log link for count outcomes, binomial likelihood and
complementary log-log link for time-to-event outcomes, and normal likelihood and identity link for continuous outcomes. We will
perform a fixed-effect model and random-effects model for the network meta-analysis. We will report both models for comparison with
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the reference group in a forest plot. For pairwise comparison, we will report the fixed-effect model if the two models reported similar
results; otherwise, we will report the more conservative model.
We will use a hierarchical Bayesian model using three different initial values using codes provided by NICE DSU (Dias 2014a). We will
use a normal distribution with large variance (10,000) for treatment effect priors (vague or flat priors). For the random-effects model,
we will use a prior distributed uniformly (limits: 0 to 5) for between-trial standard deviation but assumed similar between-trial standard
deviation across treatment comparisons (Dias 2014a). We will use a ’burn-in’ of 5000 simulations, check for convergence visually,
and run the models for another 10,000 simulations to obtain effect estimates. If we did not obtain convergence, we will increase the
number of simulations for ’burn-in’. If we do not obtain convergence still, we will use alternate initial values and priors using methods
suggested by van Valkenhoef 2012. We will also estimate the probability that each intervention ranks at one of the possible positions
using the NICE DSU codes (Dias 2014a).
Assessment of inconsistency
We will assess inconsistency (statistical evidence of the violation of transitivity assumption) by fitting both an inconsistency model and
a consistency model. We will use the inconsistency models used in the NICEDSUmanual, as we plan to use a common between-study
deviation for the comparisons (Dias 2014b). In addition, we will use the design-by-treatment full interaction model (Higgins 2012)
and IF (inconsistency factor) plots (Chaimani 2013) to assess inconsistency. In the presence of inconsistency, we will assess whether the
inconsistency is because of clinical or methodological heterogeneity by performing separate analyses for each of the different subgroups
mentioned in the ‘Subgroup analysis and investigation of heterogeneity for network meta-analysis’ section below.
If there is evidence of inconsistency, we will identify areas in the network where substantial inconsistency might be present in terms of
clinical and methodological diversities between trials and, when appropriate, limit network meta-analysis to a more compatible subset
of trials.
Direct comparison
We will perform the direct comparisons using the same codes and the same technical details.
Sample size calculations
To control for the risk of random errors, we will interpret the information with caution when the accrued sample size in the network
meta-analysis (i.e. across all treatment comparisons) was less than the required sample size (required information size). For calculation
of the required information size, see Appendix 3.
Subgroup analysis and investigation of heterogeneity for network meta-analysis
Wewill assess the differences in the effect estimates between the subgroups listed in Subgroup analysis and investigation of heterogeneity
using meta-regression with the help of the OpenBUGS code (Dias 2012a) if we include a sufficient number of trials. We will use the
potential modifiers as study level co-variates for meta-regression. We will calculate a single common interaction term (Dias 2012a). If
the 95% credible intervals of the interaction term do not overlap zero, we will consider this as evidence of difference in subgroups.
Presentation of results
We will present the effect estimates with 95% CrI for each pairwise comparisons calculated from the direct comparisons and network
meta-analysis. We will also present the cumulative probability of the treatment ranks (i.e. the probability that the treatment is within
the top two, the probability that the treatment is within the top three, etc.) in graphs (surface under the cumulative ranking curve or
SUCRA) (Salanti 2011). We will also plot the probability that each treatment is best, second best, third best etc for each of the different
outcomes (rankograms), which are generally considered more informative (Salanti 2011; Dias 2012b).
We will present the ’Summary of findings’ tables for mortality. In the ’Summary of findings for the main comparison’, we will follow
the approach suggested by Puhan et al. (Puhan 2014). First, we will calculate the direct and indirect effect estimates and 95% credible
intervals using the node-splitting approach (Dias 2010), i.e. calculate the direct estimate for each comparison by including only trials
in which there was direct comparison of treatments and the indirect estimate for each comparison by excluding the trials in which
there was direct comparison of treatments. Then we will rate the quality of direct and indirect effect estimates using GRADE which
takes into account the risk of bias, inconsistency, directness of evidence, imprecision, and publication bias (Guyatt 2011). Then, we
will present the estimates of the network meta-analysis and rate the quality of network meta-analysis effect estimates as the best quality
of evidence between the direct and indirect estimates (Puhan 2014). In addition, in the same table, we will present illustrations and
information on the number of trials and participants as per the standard ’Summary of Findings’ Table.
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Appendix 2. Search strategies
Database Time span Search strategy
The Central Register of Controlled Trials
(CENTRAL) (Wiley)
2016, Issue 3 #1 MeSH descriptor: [Hemochromatosis] explode all
trees
#2 (hemochromatos* or hemochromatos* or iron over-
load or ironoverload)
#3 #1 or #2
MEDLINE (OvidSP) January 1947 to March 2016 1. exp Hemochromatosis/
2. (hemochromatos* or hemochromatos* or iron over-
load or ironoverload).ti,ab
3. 1 or 2
4. randomized controlled trial.pt.
5. controlled clinical trial.pt.
6. randomized.ab.
7. placebo.ab.
8. drug therapy.fs.
9. randomly.ab.
10. trial.ab.
11. groups.ab.
12. 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11
13. exp animals/ not humans.sh.
14. 12 not 13
15. 3 and 14
Embase (OvidSP) January 1974 to March 2016 1. exp hemochromatosis/
2. (hemochromatos* or hemochromatos* or iron over-
load or ironoverload).ti,ab
3. 1 or 2
4. exp crossover-procedure/ or exp double-blind pro-
cedure/ or exp randomized controlled trial/ or single-
blind procedure/
5. (((((random* or factorial* or crossover* or cross over*
or cross-over* or placebo* or double*) adj blind*) or
single*) adj blind*) or assign* or allocat* or volunteer*)
.af
6. 4 or 5
7. 3 and 6
Science Citation Index Expanded (Web of
Knowledge)
January 1945 to March 2016 #1 TS=(hemochromatos* or hemochromatos* or iron
overload or ironoverload)
#2 TS=(random* OR rct* OR crossover OR masked
OR blind* OR placebo* OR meta-analysis OR system-
atic review* OR meta-analys*)
#3 #1 AND #2
World Health Organization International
Clini-
March 2016 Condition: hemochromatos* or hemochromatos* or
iron overload or ironoverload
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(Continued)
cal Trials Registry Platform Search Portal (
apps.who.int/trialsearch/Default.aspx)
ClinicalTrials.gov March 2016 Interventional Studies | (hemochromatos* OR
hemochromatos* OR iron overload OR ironoverload)
| Phase 2, 3, 4
Appendix 3. Sample size calculation
The five-year mortality in people with hereditary haemochromatosis is 5% (Wojcik 2002). The required information size based on a
control group proportion of 20%, a relative risk reduction of 20% in the intervention group, type I error of 5%, and type II error of
20% is 13,492 participants. Network analyses are more prone to the risk of random errors than direct comparisons (Del Re 2013).
Accordingly, a greater sample size is required in indirect comparisons than direct comparisons (Thorlund 2012). The power and
precision in indirect comparisons depends upon various factors, such as the number of participants included under each comparison
and the heterogeneity between the trials (Thorlund 2012). If there is no heterogeneity across the trials, the sample size in indirect
comparisons would be equivalent to the sample size in direct comparisons. The effective indirect sample size can be calculated using
the number of participants included in each direct comparison (Thorlund 2012). For example, a sample size of 2500 participants in
the direct comparison A versus C (nAC ) and a sample size of 7500 participants in the direct comparison B versus C (nBC ) results in
an effective indirect sample size of 1876 participants. However, in the presence of heterogeneity within the comparisons, the sample
size required is higher. In the above scenario, for an I2 statistic for each of the comparisons A versus C (IAC
2) and B versus C (IBC
2)
of 25%, the effective indirect sample size is 1407 participants. For an I2 statistic for each of the comparisons A versus C and B versus
C of 50%, the effective indirect sample size is 938 participants (Thorlund 2012). If there were only three groups and the sample size
in the trials is more than the required information size, we will calculate the effective indirect sample size using the following generic
formula (Thorlund 2012):
((nAC x (1 - IAC
2)) x (nBC x (1 - IBC
2))/((nAC x (1 - IAC
2)) + (nBC x (1 - IBC
2)).
There is currently no method to calculate the effective indirect sample size for a network analysis involving more than three intervention
groups.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
• There was only one comparison. So we did not perform the network meta-analysis, and assessed the comparative benefits and
harms of different interventions using standard Cochrane methodology. The methodology that we plan to use if we conduct a
network meta-analysis in future is available in Appendix 1.
• We performed Trial Sequential Analysis in addition to conventional method of assessing the risk of random errors using P-value.
N O T E S
There was considerable overlap between the ’Methods’ of this review and those of several other reviews written by the same group of
authors.
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